JP6847828B2 - 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 - Google Patents

新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 Download PDF

Info

Publication number
JP6847828B2
JP6847828B2 JP2017508102A JP2017508102A JP6847828B2 JP 6847828 B2 JP6847828 B2 JP 6847828B2 JP 2017508102 A JP2017508102 A JP 2017508102A JP 2017508102 A JP2017508102 A JP 2017508102A JP 6847828 B2 JP6847828 B2 JP 6847828B2
Authority
JP
Japan
Prior art keywords
shk
analog
seq
amino acid
analog according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017508102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525357A5 (enExample
JP2017525357A (ja
Inventor
レイモンド エス ノートン
レイモンド エス ノートン
シー チエ チャン
シー チエ チャン
マイケル ダブリュー ペニントン
マイケル ダブリュー ペニントン
クリスティン ビートン
クリスティン ビートン
ブライアン ジェイ． スミス
ブライアン ジェイ． スミス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptides International Inc
Baylor College of Medicine
Original Assignee
Peptides International Inc
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903189A external-priority patent/AU2014903189A0/en
Application filed by Peptides International Inc, Baylor College of Medicine filed Critical Peptides International Inc
Publication of JP2017525357A publication Critical patent/JP2017525357A/ja
Publication of JP2017525357A5 publication Critical patent/JP2017525357A5/ja
Priority to JP2020081545A priority Critical patent/JP6953579B2/ja
Application granted granted Critical
Publication of JP6847828B2 publication Critical patent/JP6847828B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
JP2017508102A 2014-08-15 2015-08-14 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 Active JP6847828B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020081545A JP6953579B2 (ja) 2014-08-15 2020-05-01 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014903189A AU2014903189A0 (en) 2014-08-15 Novel potassium channel blockers
AU2014903189 2014-08-15
PCT/AU2015/000487 WO2016023072A1 (en) 2014-08-15 2015-08-14 Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020081545A Division JP6953579B2 (ja) 2014-08-15 2020-05-01 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用

Publications (3)

Publication Number Publication Date
JP2017525357A JP2017525357A (ja) 2017-09-07
JP2017525357A5 JP2017525357A5 (enExample) 2018-09-20
JP6847828B2 true JP6847828B2 (ja) 2021-03-24

Family

ID=55303691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017508102A Active JP6847828B2 (ja) 2014-08-15 2015-08-14 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用
JP2020081545A Active JP6953579B2 (ja) 2014-08-15 2020-05-01 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020081545A Active JP6953579B2 (ja) 2014-08-15 2020-05-01 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用

Country Status (5)

Country Link
US (1) US10246496B2 (enExample)
EP (1) EP3180365B1 (enExample)
JP (2) JP6847828B2 (enExample)
AU (1) AU2015303825B2 (enExample)
WO (1) WO2016023072A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020127419A (ja) * 2014-08-15 2020-08-27 モナッシュ ユニバーシティ 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用
KR102533290B1 (ko) * 2022-04-14 2023-05-16 한국해양과학기술원 전압개폐 칼륨이온채널 억제 활성능을 갖는 펩타이드
KR102553070B1 (ko) * 2022-06-16 2023-07-07 한국해양과학기술원 전압개폐 칼륨이온채널 억제 활성능을 갖는 작은상자해파리 기원 펩타이드

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2474316B1 (en) * 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
PT2158213E (pt) * 2007-05-14 2012-03-27 Univ Mexico Nacional Autonoma Vm23 e vm24, dois péptidos de escorpião que bloqueiam canais de potássio de linfócitos t humanos (subtipo kv1.3) com elevada selectividade
JP2012521197A (ja) * 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
TW201542231A (zh) * 2011-06-06 2015-11-16 Kineta One Llc 以ｓｈｋ為主之醫藥組合物及其製備方法及用途
NZ709913A (en) * 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
US10246496B2 (en) * 2014-08-15 2019-04-02 La Trobe University Potassium channel blockers and use thereof in the treatment of autoimmune diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020127419A (ja) * 2014-08-15 2020-08-27 モナッシュ ユニバーシティ 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用
KR102533290B1 (ko) * 2022-04-14 2023-05-16 한국해양과학기술원 전압개폐 칼륨이온채널 억제 활성능을 갖는 펩타이드
KR102553070B1 (ko) * 2022-06-16 2023-07-07 한국해양과학기술원 전압개폐 칼륨이온채널 억제 활성능을 갖는 작은상자해파리 기원 펩타이드

Also Published As

Publication number Publication date
EP3180365B1 (en) 2021-08-18
EP3180365A4 (en) 2018-01-17
JP2020127419A (ja) 2020-08-27
JP2017525357A (ja) 2017-09-07
AU2015303825A1 (en) 2017-03-23
WO2016023072A1 (en) 2016-02-18
EP3180365A1 (en) 2017-06-21
US10246496B2 (en) 2019-04-02
JP6953579B2 (ja) 2021-10-27
AU2015303825B2 (en) 2021-01-14
US20170362286A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
AU2021212006B2 (en) Modifications and uses of conotoxin peptides
JP7280193B2 (ja) 軟骨ホーミングペプチドコンジュゲート及びその使用方法
JP6953579B2 (ja) 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用
JP7306655B2 (ja) Ｉｌ－３７バリアント
CN103403019B (zh) 具有增强的作用持续时间的工程化多肽
TW201819398A (zh) 治療性肽
JP2022545916A (ja) コンプスタチン類似体及びその医学的使用
US20230414702A1 (en) Compounds and pharmaceutical use thereof in the treatment of cancer
US20230090247A1 (en) Molecules targeting ras protein
CA3165091A1 (en) Retro-inverso peptides
CN107106643B (zh) 在癌症或癌转移的治疗或预防中的环状乙酰胆碱酯酶c端肽
US20230391838A1 (en) Conformationally-Constrained Alpha-RGIA Analogues
US20140155331A1 (en) Novel high affinity bivalent helically constrained peptide against cancer
WO2026090584A2 (en) Methods of treating peripheral nervous system myelination conditions
HK40126659A (en) Stabilized peptide-mediated targeted protein degradation
JP2012504409A (ja) ソマトスタチン類似体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200501

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200518

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201113

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210303

R150 Certificate of patent or registration of utility model

Ref document number: 6847828

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250